• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2021 12

23

TY-302 capsule was approved by NMPA for combination clinical trial

Discover More
2021 11

05

TYK Medicines’ Targeted Antitumor Innovative Drug Municipal-level Science and Technology Enterprise Research and Development Center Successfully Passed the Recognition of Huzhou Science and Technology Bureau

Discover More
2021 05

24

TYK Medicines Completed a Series B+ Financing of Nearly 400 million Yuan

Discover More
2021 03

11

TYK Medicines’ third-generation EGFR inhibitor TY-9591 approved by CDE to enter pivotal Phase III clinical trial

Discover More
2020 12

30

TYK Medicines Completed the B Round of Financing and Accelerated the Promotion of the Tumor Pipeline

Discover More
2020 11

24

TYK Medicines Innovative Drug Project was Successfully Selected 2021 Provincial Key R&D Program (Merit-based Project)

Discover More
<45678>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号